The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect isletβ-cells from apoptosis.EBI
East China Normal University
Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.EBI
Korea Research Institute of Chemical Technology
Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3ß inhibitors and neuroprotective agents.EBI
Zhejiang University
Discovery of dual death-associated protein related apoptosis inducing protein kinase 1 and 2 inhibitors by a scaffold hopping approach.EBI
Ku Leuven
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI
Cellzome
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.EBI
Harvard Medical School
Comprehensive analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI
Ambit Biosciences
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.EBI
Glaxosmithkline
Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.EBI
Zhejiang University
Targeting Death-Associated Protein Kinases for Treatment of Human Diseases: Recent Advances and Future Directions.EBI
Southwest Jiaotong University
Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2.EBI
University of North Carolina At Chapel Hill
Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-EBI
Goethe University Frankfurt
A small molecule-kinase interaction map for clinical kinase inhibitors.EBI
Ambit Biosciences
Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.EBI
University of North Carolina At Chapel Hill
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.EBI
Chinese Academy of Sciences
A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation.EBI
University of North Carolina At Chapel Hill
Discovery of 4EBI
TBA
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.EBI
Cellzome
Kinase Chemodiversity from the Arctic: The Breitfussins.EBI
Uit - The Arctic University of Norway
INHIBITORS OF 12/15-LIPOXYGENASEBDB
The General Hospital
Methods to treat lymphoplasmacytic lymphomaBDB
Dana-Farber Cancer Institute
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCVBDB
Idenix Pharmaceuticals
Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetesBDB
Merck Sharpe & Dohme